6 Dimensions Capital

6 Dimensions Capital is a global healthcare investment firm established in 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures. The firm focuses on early- and growth-stage investments in life sciences and healthcare companies, primarily across China and the United States. With offices in Shanghai, Hong Kong, Boston, and Palo Alto, 6 Dimensions Capital manages assets totaling approximately $1.6 billion across multiple funds.

The firm's investment strategy emphasizes biologics, small molecules, medical devices, diagnostics, medical services, and healthcare IT. 6 Dimensions Capital seeks to partner with entrepreneurs to build innovative healthcare businesses that benefit patients worldwide. The firm has cultivated a portfolio of more than 80 companies, including notable exits such as Grail, TScan Therapeutics, and Kymera Therapeutics.

6 Dimensions Capital's team comprises about 40 investment and operation professionals with extensive experience in the healthcare sector. The firm's disciplined investing and proactive partnering approach aims to drive value and growth for its portfolio companies, fostering synergies that lead to successful outcomes in the dynamic healthcare market.